STOCK TITAN
  1. Home
  2. News
  3. BRKR

Bruker Corporation - BRKR STOCK NEWS

Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.

Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.

The company's operations are categorized into four main segments:

  • BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
  • BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
  • BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
  • Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.

Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.

Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.

Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.

News

Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech

Rhea-AI Summary

Bruker has completed the acquisition of ELITechGroup for €870 million in cash, excluding the clinical chemistry business, becoming a leading infectious disease specialist in the in-vitro diagnostics market. ELITech offers innovative sample-to-answer systems and assays for molecular diagnostics, with FY 2023 revenue of approximately EUR 150 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
acquisition
-
News

Bruker Reports First Quarter 2024 Financial Results

Rhea-AI Summary

Bruker (BRKR) reported strong Q1 2024 financial results with revenues of $721.7 million, up 5.3% yoy. GAAP EPS was $0.35, non-GAAP EPS $0.53. FY 2024 guidance raised to $3.29-$3.35 billion, implying 11%-13% yoy growth. Acquisition of ELITech expected to boost revenue and EPS.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.31%
Tags
earnings
-
News

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Rhea-AI Summary
Bruker enhances clinical microbiology and infection diagnostics portfolio at ESCMID Global 2024 Conference with new MBT Pathfinder® IVD robot and LiquidArray® MTB-XDR panel. The company focuses on microbial identification, sepsis diagnostics, and antimicrobial susceptibility testing for improved patient treatment decisions. The pending ELITech acquisition is set to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
News

Bruker Announces Date and Time of First Quarter 2024 Earnings Release and Webcast

Rhea-AI Summary
Bruker (BRKR) has announced the date for its first quarter 2024 earnings release and webcast. The financial results will be reported on May 2, 2024, before the market opens. An earnings conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results and business trends. Investors can access the webcast through the company's website or by phone. Pre-registration is available for the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
earnings
-
News

Bruker to Acquire the NanoString Business in an Asset Deal

Rhea-AI Summary
Bruker (BRKR) has entered into a definitive acquisition agreement with NanoString Technologies, Inc., to acquire its business for approximately $392.6 million. The deal includes the acquisition of NanoString's product lines, such as nCounter®, GeoMx®, CosMx™, and AtoMx™. NanoString, a leader in gene expression profiling and spatial transcriptomics, generated revenues of around $168 million in 2023. The acquisition is expected to close in the second quarter of 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
acquisition
-
News

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Rhea-AI Summary
Bruker introduces novel magnet technology and analytical solutions to promote NMR adoption in research and biopharma industries. The Ascend Evo 600 NMR magnet offers a one-year liquid Helium hold-time, reducing refill intervals and operational costs. Additionally, the Fourier 80 platform with synTQ PAT management software enhances process analysis and quality control in API manufacturing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
News

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Rhea-AI Summary
Bruker introduces novel high-resolution solid-state NMR scientific capabilities at the 65th ENC, enabling structural biology discoveries in large proteins, membrane proteins, and protein aggregates. The new ultra-fast CP/MAS iProbe with 160 kHz MAS system provides enhanced 1H-NMR resolution and T2' times, advancing the study of biological samples. The introduction of standard-bore DNP Probes for 600 and 800 MHz expands solid-state DNP-NMR research accessibility, offering sensitivity enhancements of 50x to 200x.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
-
News

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Rhea-AI Summary
Biognosys and Alamar Biosciences announce a strategic partnership to advance scientific discovery in biofluid proteomics biomarkers. The collaboration combines Biognosys' DIA-MS platform with Alamar's NULISA assays for deep proteomics insights. The partnership will be showcased at the AACR 2024 Annual Meeting with a focus on Non-Small Cell Lung Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
partnership
-
News

Bruker Selected as ‘Company of the Year’ by Instrument Business Outlook

Rhea-AI Summary
Bruker (BRKR) has been named the Instrument Business Outlook (IBO) 'Company of the Year' for 2023 due to its impressive double-digit organic revenue growth across all major regions and business groups. The company's innovative model, management processes, and disciplined entrepreneurial culture have led to significant portfolio transformation and sustainable growth. Bruker's strategic initiatives like Project Accelerate 2.0 and Operational Excellence position it as a leader in the post-genomic era, with anticipated strong growth for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
none
News

Bruker Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Rhea-AI Summary
Bruker Corporation (BRKR) announces advancements in immunopeptidomics, glycoproteomics, and other 4D-proteomics workflows at the 20th US Human Proteome Organization Congress 2024. The company introduces innovative software, methods, and tools to enhance post-genomic research, disease biology insights, and biomarker discovery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none

FAQ

What is the current stock price of Bruker Corporation (BRKR)?

The current stock price of Bruker Corporation (BRKR) is $56.22 as of November 21, 2024.

What is the market cap of Bruker Corporation (BRKR)?

The market cap of Bruker Corporation (BRKR) is approximately 8.2B.

What does Bruker Corporation specialize in?

Bruker Corporation specializes in analytical instrumentation, offering solutions in magnetic resonance, mass spectrometry, X-ray analysis, and superconducting technologies.

How is Bruker Corporation structured?

Bruker operates in four main segments: BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

Where does Bruker generate most of its revenue?

The majority of Bruker's revenue is generated from the Asia Pacific region.

How many employees does Bruker Corporation have?

Bruker Corporation employs over 6,500 people globally.

What industries does Bruker serve?

Bruker serves the life sciences, pharmaceutical, biotechnology, and industrial production sectors.

What recent advancements has Bruker made?

Bruker has made significant advancements in mass spectrometry and has formed key partnerships with leading pharmaceutical and biotechnology firms.

What is BSI BioSpin known for?

BSI BioSpin is known for its magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.

Why are Bruker's technologies important in industrial production?

Bruker's instruments ensure quality and process reliability, which are critical for precision and performance in industrial production.

What is the BEST segment of Bruker Corporation?

BEST, or Bruker Energy & Supercon Technologies, provides superconducting materials and devices for the energy, science, and healthcare sectors.

How does Bruker Corporation contribute to scientific research?

Bruker develops state-of-the-art technologies that assist scientists and researchers in addressing complex analytical questions with precision.

Stock BRKR logo
Bruker Corporation

Nasdaq:BRKR

BRKR Rankings

#977 Ranked by Market Cap
#2060 Ranked by Dividends

BRKR Stock Data

8.25B
103.20M
31.84%
79.71%
2.51%
Medical Devices
Laboratory Analytical Instruments
Link
United States of America
BILLERICA